TGFB1 and neoplasm: In this study, the TGF-β1/COX-2 siRNA combination, prepared as a liver-targeted polypeptide nanoparticle formulation, was injected at a dose of 2 milligrams/kilogram (mg/kg) into the tail vein of tumor-bearing mice (six doses over a 3-week period).